Publication Year: 2018
-
Evaluation of immune-related markers in the circulating proteome and their association with atezolizumab efficacy in patients with 2L+ NSCLC
-
Detection of Actionable Mutations in Liquid Biopsy Samples Using Targeted Next Generation Sequencing and Droplet Digital PCR
-
Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors in 2nd Line NSCLC
-
Early diagnosis of pulmonary nodules: biomarker performance in cancer subtypes found in the PANOPTIC study
-
Early diagnosis of pulmonary nodules: biomarker performance in patients with solitary or multiple nodules in the PANOPTIC study
-
Early diagnosis pulmonary nodules: cancer diagnosis timing during CT surveillance in the PANOPTIC study
-
Mass Spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy
-
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
-
Combined plasma cfDNA mutations and a serum proteomic signature may identify non-responders to anti PD-1 treatment in NSCLC
-
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer